IMAXIO SA

Their core work

IMAXIO SA is a French biotech SME focused on malaria vaccine development, contributing proprietary vaccine platform technologies to academic research consortia. Their work centers on virus-like particle (VLP) assembly, SpyCatcher-based antigen conjugation, and multi-antigen formulation strategies that target multiple lifecycle stages of Plasmodium parasites simultaneously. In both H2020 projects they joined as a specialist industrial partner, likely supplying adjuvant systems or antigen delivery components rather than conducting primary discovery science. Their narrow, deep focus on malaria — both P. falciparum and P. vivax — positions them as a technical bridge between basic antigen research and deployable vaccine formats.

What they specialise in

How they've shifted over time

Both projects began in 2017, so there is no meaningful chronological gap between them. However, the keyword shift does reveal a species expansion: the first project (OptiMalVax) was built around Plasmodium falciparum, using a rich toolkit of multi-stage antigens and VLP/SpyCatcher assembly, while the second (MultiViVax) introduced Plasmodium vivax as a distinct target. This suggests IMAXIO's platform is species-agnostic and they were sought out to apply the same antigen-display technology to a neglected second malaria parasite. The trajectory is one of expanding taxonomic coverage rather than changing technical approach.

IMAXIO appears to be broadening their malaria vaccine platform from a single-species tool (P. falciparum) to a multi-species capability, which would make them relevant to any consortium pursuing a universal or combination malaria vaccine.

How they like to work

IMAXIO has never coordinated an H2020 project — they join as a participant in consortia led by others, which is typical for SMEs contributing a proprietary platform or component. Despite only two projects, they accumulated 20 distinct consortium partners across 8 countries, suggesting they work in mid-to-large research consortia rather than small bilateral partnerships. Their role is that of an industrial specialist: they bring a specific technology (VLP, SpyCatcher, adjuvant) that academic partners need but cannot easily produce themselves.

IMAXIO has connected with 20 unique consortium partners across 8 countries from just two projects, indicating they joined well-networked RIA consortia rather than narrow bilateral efforts. Their geographic spread across 8 countries reflects the international nature of malaria vaccine research.

What sets them apart

IMAXIO occupies a rare niche as an industrial SME with deep malaria-specific vaccine platform expertise — most H2020 malaria projects are dominated by academic institutions and large pharma, making a mid-sized French biotech unusual. Their combination of VLP scaffolds, SpyCatcher conjugation chemistry, and adjuvant formulation in a single SME means they can take a defined antigen sequence and convert it into a testable vaccine candidate within one organization. For a consortium building a new malaria vaccine program, IMAXIO offers a translation layer that academic partners typically lack.

Highlights from their portfolio

• OptiMalVax
  The more technically complex of the two projects, targeting all three lifecycle stages of P. falciparum simultaneously using VLP and SpyCatcher assembly — the broadest antigen coverage IMAXIO has been associated with.
• MultiViVax
  Focuses on Plasmodium vivax, a neglected species compared to P. falciparum despite causing the majority of malaria cases outside Africa — demonstrating IMAXIO's platform versatility beyond the most-funded malaria target.